Eliglustat GZ385660; Imiglucerase GZ437843
Проводит Sanofi
Страница компанииOpen Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03485677/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 2–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 57 чел. во всех странах исследования.
- Плановая дата окончания (12.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 15 · невключение: 9
Критерии включения
- The participant were 2 to <18 years old at the time of informed consent.
- Male and female participants with a clinical diagnosis of Gaucher disease (GD) type 1 or type 3 with documented deficiency of acid beta-glucosidase activity by enzyme assay and glucocerebrosidase (GBA) genotype.
- Postmenarchal female participants had a documented negative pregnancy test prior to enrollment and throughout the study. Participants had to be willing to practice true abstinence in line with their preferred and usual lifestyle, or used a medically accepted form of contraception throughout the study.
- Cohort 1 (Eliglustat monotherapy):
- Participants must had been receiving an enzyme replacement therapy (ERT) for a minimum of 24 months at a monthly dose equivalent to 30 U/kg to 130 U/kg of Cerezyme® (imiglucerase) with treatment ongoing at the time of enrollment. Participants had to be at pre-specified treatment goals, as defined by:
- Hemoglobin level for ages 2 to <12 years: ≥11.0 g/dL; for ages 12 to <18 years: ≥11.0 g/dL for females and ≥12.0 g/dL for males;
- Platelet count ≥100,000/mm3;
- Spleen volume <10.0 multiples of normal (MN);
- Liver volume <1.5 MN;
- Absence of GD related pulmonary disease, and severe bone disease, as defined below for Cohort 2.
- Cohort 2 (Eliglustat plus imiglucerase):
- Participants must had been receiving an ERT for a minimum of 36 months at a dose equivalent to at least 60 U/kg of imiglucerase every 2 weeks, or at the maximum dose locally approved, at the time of enrollment with treatment ongoing at the time of enrollment and the dose stable for at least the 6 months preceding enrollment. Participants must had severe clinical manifestations of GD, as defined by the presence of at least one of the following:
- GD related pulmonary disease such as interstitial lung disease (ILD). The diagnosis of ILD had to confirmed by the presence of reticulonodular densities on chest X-ray; AND/OR
- Symptomatic bone disease characterized by pathological fracture, osteonecrosis, osteopenia/osteoporosis, or bone crisis occurring in the 12 months prior to enrollment; AND/OR
- Persistent thrombocytopenia (<80,000/mm3) related to GD.
Критерии невключения
- Substrate reduction therapy for GD within 6 months prior to enrollment.
- Partial or total splenectomy if performed within 2 years prior to enrollment
- The participant was transfusion dependent, a history of esophageal varices or liver infarction, elevated liver enzymes, significant congenital cardiac defect, coronary artery disease or left sided heart failure; clinically significant arrhythmias or conduction defect such as Type 2 second degree or third degree atrioventricular (AV) block, complete bundle branch block, prolonged QTc interval, or sustained ventricular tachycardia (VT).
- The participant had any clinically significant disease other than GD.
- The participant had neurological symptoms other than oculomotor apraxia at study entry.
- The participant had received an investigational product within 30 days prior to enrollment.
- The participant was unable to receive treatment with imiglucerase due to a known hypersensitivity or was unwilling to receive imiglucerase treatment every 2 weeks.
- The participant had a known hereditary galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption, or is a CYP2D6 ultra-rapid metabolizer or indeterminate metabolizer.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT03485677 · запись обновлена в реестре 16 июня 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 8
- Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax — Weeks 2, 13, 26 and 52
- Assessment of PK parameter of eliglustat: AUC — Weeks 2 and 52
- Adverse Events — Up to Week 364
Цель исследования
Primary Objective:
Evaluated the safety and pharmacokinetics of eliglustat in pediatric participants (≥2 to \<18 years old).
Secondary Objective:
Evaluated the efficacy of eliglustat and quality of life in pediatric participants (≥2 to \<18 years old).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03485677 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.